Tascilar, Mehmet EmreBilir, PelinAkinci, AysehanKose, KenanAkcora, DilekInceoglu, DenizFitoz, Suat Omer2024-08-042024-08-0420110041-4301https://hdl.handle.net/11616/95354Gonadotropin-releasing hormone analog (GnRHa) therapy is used in idiopathic central precocious puberty (ICPP) worldwide. It has also been shown that during this therapy, body mass index (BMI) increases slightly as a side effect. We investigated the side effects of GnRHa treatment in ICPP on body composition and insulin resistance (IR). Twenty girls (7.55 +/- 1.02 y) with ICPP were treated with GnRHa (leuprolide) for an average of 20.83 +/- 4.8 months. Bioelectrical Impedance Analysis (BIA) was used to measure the body's fat balance. Nine patients out of 20 (45%) had significant gain weight. We showed a significant elevation in trunk fat mass compare to baseline values (p<0.01). These nine patients had high homeostasis model assessment (HOMA)-IR and low glucose/insulin (G/I) index. This study showed a slight increase in BMI, moderate increase in total body fat, and exaggerated elevation in trunk fat mass and IR in GnRHa-treated ICPP children.eninfo:eu-repo/semantics/closedAccessleuprolideprecocious pubertyobesitybody fat compositionbody mass indexhyperinsulinismArticle5312733215343362-s2.0-79958712295Q3WOS:000289862600005Q4